What ChondroFiller actually needs to work

The clinical logic behind ChondroFiller is straightforward once you understand what the product itself does not do. Injected under image guidance as an in-situ gelling collagen scaffold, it creates the right biological environment — but it brings no cells of its own. The patient's progenitor cells must migrate into the matrix, differentiate into chondrocytes, and gradually replace the scaffold with repair tissue. The body does the rebuilding; the scaffold simply holds the space.

For that to happen, two conditions must be present simultaneously. First, the defect must be focal and well-bordered, with a rim of healthy surrounding cartilage to contain the gel mechanically and supply the cells that will populate it. Second, the patient's local cell biology must be sufficiently intact to mount that response.

Every contraindication discussed in the sections that follow traces back to one or both of these requirements being unmet — either the structural containment is absent, or the biological capacity to repair is compromised.

Advanced or diffuse knee OA: the most common disqualifier

Kellgren-Lawrence Grade IV osteoarthritis is the single most common reason a knee patient is found to be outside ChondroFiller's clinical scope. At this stage, cartilage loss is diffuse and generalised across the joint surface — there is no healthy surrounding rim within which the scaffold can sit, and no stable border from which host cells can migrate inward. Both structural requirements fail at once.

Closely related are kissing lesions, where the opposing articular surfaces are both damaged. ChondroFiller addresses a single chondral surface; where both sides of a joint compartment are compromised, focal repair on one side cannot restore a functioning articulation.

When degeneration has extended into multiple compartments — or across the knee globally — the joint has passed the threshold where cartilage regeneration is a meaningful conversation. At that point, the focus appropriately shifts toward managing load and symptoms, or toward surgical reconstruction of the joint itself.

A further structural barrier is significant subchondral bone loss beneath the defect. A collagen scaffold operates at the chondral level only; it cannot correct the bony architecture beneath it. Where bone reconstruction is needed, that work would need to precede any cartilage-layer repair.

Patients who present with these features are not being turned away from treatment — they are being directed toward the right conversation, which is more likely to involve unicompartmental or total knee arthroplasty, or a structured programme of load management and symptom control. A consultant assessment clarifies which pathway genuinely fits the imaging.

Defect size: why smaller and larger lesions may need different routes

Defect area — measured precisely on MRI — is one of the more tractable pieces of the suitability puzzle, because published data give relatively clear size brackets to work with.

For small lesions of roughly 1–2 cm² or under, bone marrow stimulation techniques and osteochondral autograft transfer remain established, well-evidenced first-line options. These are appropriate choices for their size range — proportionate to the lesion, not inferior alternatives to scaffold treatment.

ChondroFiller's evidence base covers focal defects up to 6 cm² in a single treatment session. The practical case is strongest in the 2–6 cm² focal range, where patients with a well-contained lesion and healthy surrounding cartilage sit within the published dataset.

At the larger end of that window — defects of 3 cm² and above — cell-based repair procedures carry level-I evidence. The SUMMIT trial demonstrated improved KOOS pain and function scores at both two and five years for matrix-induced autologous chondrocyte implantation compared with bone marrow stimulation in this size bracket; these procedures are a relevant alternative to weigh when defects approach or exceed that threshold.

One point worth noting: symptom severity does not reliably predict defect size. A small lesion in a mechanically sensitive location can generate substantial pain; a larger lesion may remain relatively quiet. MRI gives the consultant the actual measurement. Size, location, containment, and surrounding cartilage quality are all considered together — no single dimension determines the pathway on its own.

Biological factors that block safe or effective scaffold integration

Some contraindications to ChondroFiller have nothing to do with defect size or wear pattern — they concern the biological environment of the joint itself.

Active intra-articular infection is an absolute bar. A contaminated joint cannot support scaffold integration, and an implanted collagen matrix in an infected space risks acting as a nidus for persistent infection. Treatment cannot proceed until the joint is fully clear.

Active inflammatory arthropathy — rheumatoid arthritis with ongoing synovitis being the clearest example — creates a cytokine-rich environment that disrupts the cell recruitment the scaffold depends on. This applies when disease is active; patients with well-controlled inflammatory arthritis present a different clinical picture, and individual assessment rather than blanket exclusion is the appropriate approach.

Collagen allergy is a hard contraindication. ChondroFiller is derived from murine (mouse) Type I collagen; known hypersensitivity to animal-derived collagen makes the product unsuitable regardless of the joint presentation.

Beyond these absolutes, regenerative capacity is assessed individually. The scaffold provides no cells of its own — it relies on the patient's progenitor cells migrating in and maturing into cartilage tissue. Systemic illness, ongoing immunosuppression, or other factors that meaningfully impair that biology may limit what the scaffold can achieve. Suitability here is determined at consultation, not by a fixed rule.

Age is not a reliable proxy for that capacity. Chronological age above 50 is not, on its own, a disqualifying factor — registry evidence suggests patients aged 50–69 achieve comparable outcomes to younger cohorts following single-stage focal chondral repair.

Mechanical malalignment: why the joint axis must be right first

The mechanical axis of the knee determines how load is distributed across its compartments. Significant varus ('bow-legged') deformity concentrates force through the medial side; significant valgus ('knock-kneed') deformity does the same on the lateral side. A focal cartilage repair sitting in the overloaded compartment faces chronic mechanical stress from the moment weight-bearing begins — an environment that can compromise scaffold integration before repair tissue has had time to mature.

ChondroFiller addresses the defect itself but does not alter joint geometry. In a meaningfully malaligned knee, that underlying mechanical problem remains, and the scaffold works against those forces from day one.

Where malalignment is significant, a realignment procedure — most commonly high tibial osteotomy for medial compartment overload — may need to be completed before or alongside focal repair, providing a biomechanically fairer environment for healing. This is a sequencing decision, not a permanent disqualification from cartilage repair. No single angular threshold automatically determines that an osteotomy is required; the degree of deformity, imaging findings, and functional loading pattern are weighed together on an individual basis.

Alignment assessment forms part of the pre-treatment workup for cartilage repair patients. Objective gait and biomechanical evaluation — using tools such as MAI Motion® gait analysis — helps the consultant characterise how load is distributed across the joint and whether realignment must precede any scaffold treatment.

How suitability is determined at Lincolnshire Knee

MRI is the clinical gate. Symptoms and self-reported severity alone cannot establish whether a defect is focal, contained, and bordered by healthy cartilage — only imaging can. At Lincolnshire Knee, onMRI™ AI-assisted analysis supports precise defect characterisation, including cartilage segmentation and T2 mapping, giving the consulting clinician a detailed picture of defect dimensions, subchondral bone condition, and surrounding tissue quality before the appointment begins.

From that imaging baseline, the consultation maps defect size, border quality, mechanical alignment, and systemic health together. No single factor decides suitability in isolation. A patient excluded from ChondroFiller by defect size may be well suited to an alternative focal repair technique; a patient excluded by diffuse wear is more likely a candidate for a different pathway altogether. The sections above describe what ChondroFiller cannot address — the consultation's purpose is to establish what, for a specific knee, it can.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without GP referral, with clinics at Sleaford NG34 and Grantham NG31. A confirmed diagnosis is not required to book an assessment at lincolnshireknee.co.uk.